Insulet Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Insulet develops and sells the Omnipod insulin-delivery system and provides drug-delivery products. Figures are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change / context |
|---|---|---|---|
| Total revenue | $295.4 | $252.3 | Up 17.1%; up 19.3% at constant currency |
| Gross profit / margin | $209.7 / 71.0% | $167.5 / 66.4% | Margin improved 460 basis points |
| Operating income | $37.9 | $16.3 | Higher revenue and gross margin exceeded expense growth |
| Net income | $27.8 | $0.0 | Basic and diluted EPS were $0.40 |
| Net interest expense | $8.9 | $13.4 | Lower mainly because of adoption of ASU 2020-06 |
| Cash used in operations | $13.7 | $35.1 | Working-capital outflow was $68.0 |
| Cash used in investing | $46.9 | $22.7 | Includes $26.0 acquisition payment and $5.0 strategic investment |
| Cash used in financing | $20.3 | $28.4 | Includes debt repayments and taxes on vested equity awards |
Revenue and operating trends
- U.S. Omnipod revenue rose 21.5% to $174.1; international Omnipod revenue rose 6.1% to $95.4, or 12.5% excluding unfavorable currency effects. Drug Delivery revenue increased 35.6% to $25.9, primarily due to production timing.
- U.S. related-party revenue was $48.4 versus $2.8 a year earlier. Management attributed the increase primarily to a shift in certain revenue between distributors, rather than solely to underlying growth.
- Gross margin improvement reflected manufacturing efficiencies and higher average selling prices associated with pharmacy-channel growth. R&D increased 5.9% to $43.1; SG&A increased 16.5% to $128.7, including increased staffing, commercial investment, and travel.
- Net income improved from breakeven. Adjusted EBITDA, a non-GAAP measure, was $63.0 versus $35.1.
Balance sheet, liquidity and debt
- At March 31, cash and cash equivalents were $709.6, down from $791.6 at year-end. Cash, cash equivalents and restricted cash totaled $724.9.
- Total debt, net, was $1,416.2, including $800.0 principal of 0.375% convertible notes due 2026 and a $496.3 term loan due 2028. No borrowings were outstanding under the $60.0 revolving facility.
- Management said existing liquidity should fund projected operating, investing and debt-service needs for at least the next 12 months. The company had $314.8 of inventory, up from $303.2, reflecting a planned build to support demand.
- Operating cash use reflected working-capital needs, including higher receivables and inventory and annual bonus payments. Capital expenditures were $12.8; management expected 2022 capital spending to increase as it invests in manufacturing capacity.
Outlook, risks and notable items
- Management expected 2022 gross margin of 67%–68%, below Q1’s 71.0%, citing product mix, Omnipod 5 production costs, inflation, and supply-chain disruption. Productivity and manufacturing improvements and pharmacy-channel growth were expected to partly offset these pressures.
- Management expected strong U.S. Omnipod growth, continued international growth partly offset by competition, and lower full-year Drug Delivery revenue because pandemic-period production levels had been elevated. R&D, SG&A, and capital expenditures were expected to increase in 2022.
- Omnipod 5 received FDA clearance in January for people aged six and older with type 1 diabetes; limited release began in February, with full U.S. release expected during 2022. European approval remained under review. Management also planned a randomized control trial to support reimbursement efforts.
- Supply-chain constraints and inflation were expected to pressure margins and net income. Other disclosed risks include competition, reimbursement access, dependence on suppliers and the Omnipod platform, regulatory and international-market risks, and product and cybersecurity risks.
- Roche patent litigation remained pending, with trial scheduled for July 25, 2022. Insulet said it could not reasonably estimate a potential loss or range, which could be material; Roche was not seeking injunctive relief.
- On May 4, 2022, the company announced that CEO Shacey Petrovic would step down effective June 1, 2022, and that director Jim Hollingshead would succeed her. The filing also reports a January acquisition of SMA wire-assembly assets for $29.0, including a $3.0 holdback.
- Adoption of ASU 2020-06 increased reported debt and reduced additional paid-in capital, with an opening-equity adjustment; it also reduced noncash convertible-note interest expense. Management reported effective disclosure controls and no material change to previously disclosed risk factors.
Important facts for investors to verify
- Whether Omnipod 5 achieves the expected full-year launch, adoption, reimbursement progress, and international regulatory approvals.
- Whether full-year gross margin falls within the 67%–68% outlook amid inflation, supply constraints, and higher product costs.
- How much U.S. growth reflects underlying customer and pharmacy-channel expansion versus distributor revenue shifts, and whether international competition affects growth.
- Whether working-capital demands and planned manufacturing investments continue to consume cash, and whether liquidity remains sufficient alongside debt obligations.
- Developments in the Roche litigation, including trial outcome and potential financial exposure, and execution of the CEO transition.